Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/DeltaFosB expression

Neuroscience Letters

Volumn 541, Issue , 2013, Pages 126-131

  Padovan Neto, Fernando Eduardo ^a   Ferreira, Nádia Rubia ^a   de Oliveira Tavares, Danielle ^a   de Aguiar, Daniele ^b   da Silva, Célia Aparecida ^a   Raisman Vozari, Rita ^c,d   Del Bel, Elaine ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

6 Hydroxydopamine; 7 Nitroindazole; Abnormal involuntary movements; Dyskinesia; FosB FosB; L DOPA; Nitric oxide

Indexed keywords

7 NITROINDAZOLE; BENSERAZIDE PLUS LEVODOPA; NEUROTOXIN; SODIUM CHLORIDE; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPLETION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DYSKINESIA; FEEDING; IN VIVO STUDY; LIMB; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MICROINJECTION; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ROTAROD TEST;

ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DYSKINESIA, DRUG-INDUCED; INDAZOLES; LEVODOPA; MALE; MICROINJECTIONS; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE TYPE I; OXIDOPAMINE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR;

EID: 84876409647     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.015     Document Type: Article

References (50)

1. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
2. Andersson M., Konradi C., Cenci M.A. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J. Neurosci. 2001, 21:9930-9943.
3. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., Bloch B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of l-DOPA-induced dyskinesia. J. Neurosci. 2009, 29:4829-4835.
4. Berton O., Guigoni C., Li Q., Bioulac B.H., Aubert I., Gross C.E., Dileone R.J., Nestler E.J., Bezard E. Striatal overexpression of DeltaJunD resets l-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol. Psychiatry 2009, 66:554-561.
5. Brown L.L., Sharp F.R. Metabolic mapping of rat striatum: somatotopic organization of sensorimotor activity. Brain Res. 1995, 686:207-222.
6. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010, 9:1106-1117.
7. Canales J.J., Graybiel A.M. A measure of striatal function predicts motor stereotypy. Nat. Neurosci. 2000, 3:377-383.
8. Cao X., Yasuda T., Uthayathas S., Watts R.L., Mouradian M.M., Mochizuki H., Papa S.M. Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J. Neurosci. 2010, 30:7335-7343.
9. Cenci M.A. Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 2002, 23:105-109.
10. Cenci M.A., Lee C.S., Björklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
11. Cenci M.A., Tranberg A., Andersson M., Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-DOPA treatment. Neuroscience 1999, 94:515-527.
12. Darmopil S., Martín A.B., De Diego I.R., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation. Biol. Psychiatry 2009, 66:603-613.
13. Del Bel E.A., Guimarães F.S., Bermúdez-Echeverry M., Gomes M.Z., Schiaveto-de-souza A., Padovan-Neto F.E., Tumas V., Barion-Cavalcanti A.P., Lazzarini M., Nucci-da-Silva L.P., de Paula-Souza D. Role of nitric oxide on motor behavior. Cell. Mol. Neurobiol. 2005, 25:371-392.
14. Del-Bel E., Padovan-Neto F.E., Raisman-Vozari R., Lazzarini M. Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment. Curr. Pharm. Des. 2011, 17:471-488.
15. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
16. Dickson P.R., Lang C.G., Hinton S.C., Kelley A.E. Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study. Neuroscience 1994, 61:81-91.
17. Ebrahimi A., Pochet R., Roger M. Topographical organization of the projections from physiologically identified areas of the motor cortex to the striatum in the rat. Neurosci. Res. 1992, 14:39-60.
18. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 2002, 22:5042-5054.
19. Gomes M.Z., Raisman-Vozari R., Del Bel E.A. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res. 2008, 1203:160-169.
20. Guigoni C., Doudnikoff E., Li Q., Bloch B., Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol. Dis. 2007, 26:452-463.
21. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am. J. Psychiatry 1996, 153:151-162.
22. Iravani M.M., Stockwell K.A., Tayarani-Binazir K., Jackson M.J., Smith L.A., Rose S., Jenner P. Inhibition of neuronal nitric oxide synthase as a novel target for suppression of levoda-induced dyskinesia in primates. Neurosci. Meeting Planner Soc. Neurosci. 2008, Abstr 139. 15/M6.
23. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677.
24. Kelley A.E., Lang C.G., Gauthier A.M. Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology (Berl) 1988, 95:556-559.
25. Kelz M.B., Chen J., Carlezon W.A., Whisler K., Gilden L., Beckmann A.M., Steffen C., Zhang Y.J., Marotti L., Self D.W., Tkatch T., Baranauskas G., Surmeier D.J., Neve R.L., Duman R.S., Picciotto M.R., Nestler E.J. Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature 1999, 401:272-276.
26. Kuczenski R., Segal D.S. Sensitization of amphetamine-induced stereotyped behaviors during the acute response. J. Pharmacol. Exp. Ther. 1999, 288:699-709.
27. Lane E., Dunnett S. Animal models of Parkinson's disease and l-DOPA induced dyskinesia: how close are we to the clinic?. Psychopharmacology (Berl) 2008, 199:303-312.
28. Lindgren H.S., Rylander D., Iderberg H., Andersson M., O'Sullivan S.S., Williams D.R., Lees A.J., Cenci M.A. Putaminal upregulation of FosB/_FosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. J. Parkinson's Dis. 2011, 1:347-357.
29. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
30. Mitkovski M., Padovan-Neto F.E., Raisman-Vozari R., Ginestet L., da-Silva C.A., Del-Bel E.A. Investigations into potential extrasynaptic communication between the dopaminergic and nitrergic systems. Front Physiol. 2012, 3:372.
31. Muriel M.P., Bernard V., Levey A.I., Laribi O., Abrous D.N., Agid Y., Bloch B., Hirsch E.C. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann. Neurol. 1999, 46:103-111.
32. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
33. Novaretti N., Padovan-Neto F.E., Tumas V., da-Silva C.A., Del Bel E.A. Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats. Braz. J. Med. Biol. Res. 2010, 43:1047-1053.
34. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann. Neurol. 2000, 47:S22-S32. discussion S32-24.
35. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5:677-687.
36. Padovan-Neto F.E., Echeverry M.B., Chiavegatto S., Del-Bel E. Nitric oxide synthase inhibitor improves de novo and long-term l-DOPA-induced dyskinesia in hemiparkinsonian rats. Front Syst. Neurosci. 2011, 5:40.
37. Padovan-Neto F.E., Echeverry M.B., Tumas V., Del-Bel E.A. Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience 2009, 159:927-935.
38. Pavón N., Martín A.B., Mendialdua A., Moratalla R. ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 2006, 59:64-74.
39. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego. 4th ed.
40. Pierucci M., Galati S., Valentino M., Di Matteo V., Benigno A., Pitruzzella A., Muscat R., Di Giovanni G. Nitric oxide modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. CNS Neurol. Disord. Drug Targets 2011, 10:777-791.
41. Pisa M. Regional specialization of motor functions in the rat striatum: implications for the treatment of parkinsonism. Prog. Neuropsychopharmacol. Biol. Psychiatry 1988, 12:217-224.
42. Salamone J.D., Mahan K., Rogers S. Ventrolateral striatal dopamine depletions impair feeding and food handling in rats. Pharmacol. Biochem. Behav. 1993, 44:605-610.
43. Sammut S., Bray K.E., West A.R. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity. Psychopharmacology (Berl) 2007, 191:793-803.
44. Sammut S., Dec A., Mitchell D., Linardakis J., Ortiguela M., West A.R. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neuropsychopharmacology 2006, 31:493-505.
45. Sammut S., Park D.J., West A.R. Frontal cortical afferents facilitate striatal nitric oxide transmission in vivo via a NMDA receptor and neuronal NOS-dependent mechanism. J. Neurochem. 2007, 103:1145-1156.
46. Takuma K., Tanaka T., Takahashi T., Hiramatsu N., Ota Y., Ago Y., Matsuda T. Neuronal nitric oxide synthase inhibition attenuates the development of l-DOPA-induced dyskinesia in hemi-Parkinsonian rats. Eur. J. Pharmacol. 2012, 683:166-173.
47. Tekumalla P.K., Calon F., Rahman Z., Birdi S., Rajput A.H., Hornykiewicz O., Di Paolo T., Bédard P.J., Nestler E.J. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol. Psychiatry 2001, 50:813-816.
48. West A.R., Tseng K.Y. Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of parkinson's disease?. Front Syst. Neurosci. 2011, 5:55.
49. Winkler C., Kirik D., Björklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
50. Yuste J.E., Bermúdez M., Bernal F.R., Barcia C., Martin J., Del Bel E., Villalba E.F., Herrero M.T. NOS inhibitors improve l-DOPA-induced dyskinesias in experimental models of Parkinsonism. Mov. Disord. 2011, 26:257-258.